The company's market valuation went up by Rs 713 crore to Rs 11,516.03 crore.
On the volume front, 4.67 lakh shares of the company were traded on BSE and over 32 lakh shares changed hands at NSE during the day.
Drug firm Jubilant Life Sciences yesterday said its consolidated net profit zoomed nearly 14-fold to Rs 149.03 crore for the March quarter on robust sales.
The company had posted a net profit of Rs 10.86 crore for the corresponding period of the previous fiscal, it said in a filing to BSE.
Consolidated total revenue from operations also rose to Rs 1,641.42 crore for the quarter under consideration as against Rs 1,515.83 crore for the same period a year ago.
For the fiscal year ended March this year, the net profit of the company rose to Rs 574.62 crore as against Rs 386.82 crore a year ago.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.